572 results
The primary objective is to compare the efficacy of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival (PFS) in subjects with newly diagnosed…
To evaluate the efficacy of danicopan as compared to placebo as add-on therapy to a C5 inhibitor at 12 weeks.
The aim of this proof-of-concept study is to analyze the use of heart rate based variables using the Apple Watch:A) To predict Acute Chest Syndrome in patients hospitalized patients for painful crises;B) To predict painful crises in ambulant…
The primary objective of this study is:- To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA)The secondary objectives of this study are:-To compare the proportion of subjects with wAIHA…
- To assess platelet (dys)function in adults with 22q11.2DS and its association with bleeding history.- To identify alterations in metabolic pathways in 22q11.2DS that may be of relevance to mechanisms underlying neurodevelopmental and…
To evaluate management strategies in premenopausal women with heavy menstrual bleeding associated with factor Xa inhibitor therapy.
To evaluate the prevalence of C-TMA in patients presenting with TMA, either with coexisting conditions or not. Furthermore, (i) the diagnostic performance of an in-house developed ex vivo test, (ii) dynamics of complement measures during follow-up,…
This study is being conducted to determine the safety and efficacy of the study drug BIVV001 when used as a once-a-week prophylaxis treatment or as an on-demand (as-needed) treatment for bleeding in patients 12 years and older with severe hemophilia…
Main objective: - To investigate pyruvate kinase thermal stability in haemoglobinopathies.Secondary objectives: - To investigate the possibility of stimulation of PK activity and thermal stability by use of allosteric activators- To investigate…
- Identify hemato-oncology patients and conditions with a high versus a low bleeding risk, by epidemiological research and a short questionnaire. - Investigate the association of bleeding related biomarkers with bleeding.
Aim of the study is to show the feasibility of pneumatic tube transport of thrombocyte concentrates. The efficacy will be measured by thrombocyte increment (CCI) and thrombocyte funtion analysis. This shall lead to routine transportation of TC*s to…
To evaluate possible changes in immune profiles and platelet function after start of a TPO-RA.
The primary objective of this randomized controlled trial is to study the effectiveness of lymphaticovenous anastomosis (LVA) compared to complex decongestive therapy (CDT) in terms of health-related quality of life (HRQoL). Secondary objectives are…
The primary aim of this project is to analyze the association between factor VIII and factor IX plasma levels and the bleeding phenotype.
Objective part I: To detect subclinical (inflammatory) joint changes using ultrasound and MRI in severe haemophilia patients with low bleeding rates and to correlate these findings with biochemical markers of joint tissue turnover.Objective part II…
The aim of SPIRIT is to investigate the mechanisms of the immunological tolerance to FVIII in patients with hemophilia A aged younger than 18 years using NFT for prophylaxis.
The primary goal of this study is to compare serial paired POC and venous INR measuremtents and to distill an individual conversion factor per patient, enabling the ungoing use of POC-INR measurement also in this patient group.
The characterization of the immunophenotypic profile of PBMC subsets in steady state SCD patients. The determination of general T cell function in SCD patients. Both will be used as reference profiles in further research evaluating immune…
This study has been transitioned to CTIS with ID 2023-510455-28-00 check the CTIS register for the current data. This study is being carried out to investigate the treatment with benralizumab in patients with active HES.The purpose of this study is…
This study has been transitioned to CTIS with ID 2023-508929-27-00 check the CTIS register for the current data. -To evaluate the long-term safety of BIVV001 in previously treated patients with hemophilia A.-To evaluate the efficacy of BIVV001 as a…